ModifiedUnitedHealthcarePolicy CS079PA.T

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Pennsylvania Only)

Policy governing coverage and medical necessity criteria for minimally invasive endoscopic and laparoscopic procedures to treat upper gastrointestinal conditions (e.g., gastroparesis, achalasia, GERD) for UnitedHealthcare members in Pennsylvania.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Pennsylvania Only)

Policy CodePolicy CS079PA.T

Change TypeMaterial additions and coding updates

Effective DateApr 1, 2026

Next Review Date

Key ActionSubmit prior authorization with documentation of refractory symptoms, prior conservative treatments, and supporting diagnostic testing to demonstrate medical necessity.

SourceLink

POLICY UPDATE CHANGES

Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Medical records documentation requirements were expanded to state that benefit coverage is determined by federal, state, or contractual requirements and that medical records must fully support medical necessity and be made available upon request.

Applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added.

Medical records documentation requirements were expanded to specify the types of documentation that must support medical necessity and that records must be made available upon request.

CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to the applicable codes list.

Description of Services, Clinical Evidence, FDA, and References sections were updated to reflect current information.

Definition of 'Gastroparesis' was updated.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Pennsylvaniajurisdiction

7CPT codes added

83% vs 81.7%POEM 2-yr success (Werner)

90%POEM post-Heller success

70%G-POEM ~1yr success

151Enterra cohort

Coverage and Medical Necessity Criteria

Covered and not medically necessary procedures

Covered when ALL of the following are met for each specific intervention:

Gastric electrical stimulation (GES): GES is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Refer to FDA/HDE information as applicable

Open or laparoscopic approaches included

Per oral endoscopic myotomy (POEM): POEM is proven and medically necessary for treating individuals with achalasia or diffuse esophageal spasm.

Clinical success commonly defined by Eckardt score ≤ 3

POEM—other indications: POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

POEM for indications other than achalasia or diffuse esophageal spasm is NMN

G-POEM: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis.

Insufficient quality evidence and long-term data

GES — guideline-based conditional coverage

Guideline-based coverage consideration

GES consideration: GES may be considered for medically refractory diabetic or idiopathic gastroparesis as a humanitarian use device per ACG; AGA suggests GES can be considered for refractory/intractable nausea and vomiting after failure of standard therapy and not on opioids.

Conditional recommendation based on low to moderate quality evidence

Pyloroplasty / Pyloric interventions

Pyloric interventions and surgical options

Pyloroplasty/PI: Systematic reviews report pyloroplasty and other pyloric interventions provide symptom improvement and improved gastric emptying; some reviews suggest pyloric interventions may provide more consistent symptom relief than GES and can be considered a first-line surgical option for refractory gastroparesis.

Consider patient selection; evidence includes variable success rates

POEM — coverage considerations

POEM for achalasia and spastic esophageal disorders

POEM effectiveness: Multiple randomized trials, systematic reviews, and guideline updates report POEM is effective for achalasia (types I–III) with clinical success rates generally high and non-inferior to laparoscopic Heller myotomy; POEM may have higher rates of gastroesophageal reflux post-procedure which requires management.Eckardt ≤ 3 typically used for success

Evidence includes RCTs (Werner) and multiple systematic reviews; monitor for reflux

Z-POEM — investigational/limited

Z-POEM for Zenker's diverticulum

Z-POEM: Current evidence is limited, largely retrospective, and short-term; Z-POEM may be a feasible alternative to flexible endoscopic septotomy in expert hands but long-term comparative effectiveness and durability remain uncertain.

High risk of bias in available studies; prospective comparative data needed

Coverage considerations for Z-POEM, G-POEM, and Stretta

Evidence summaries indicate limited or low-quality data for these procedures; coverage decisions should be based on high-quality comparative data and documented refractory disease.

G-POEM considered: Consider G-POEM for patients with refractory gastroparesis after failed medical/dietary therapy and objective testing (e.g., abnormal gastric emptying study) when performed in experienced centers and when documented evidence shows potential benefit.Trials referenced GCSI >2.3 or severe symptoms

Evidence quality is low to very low; RCTs small; long-term durability uncertain

Z-POEM considered: Z-POEM may be considered as an alternative to flexible endoscopic septotomy in expert hands, but long-term comparative effectiveness is uncertain; consider only when documented clinical rationale and operator expertise exist.

Insufficient high-quality long-term data; higher recurrence reported in some cohorts

Stretta (radiofrequency) considered: Stretta may be considered investigational/unproven due to inconsistent RCT and observational evidence; when considered, document failed PPI therapy and refractory GERD symptoms.

Evidence-based coverage considerations

Evidence-based considerations from this section (informational):

Evidence summary: Randomized and nonrandomized studies indicate some endoscopic procedures (EFTP/TIF, MUSE, Stretta) can improve GERD symptoms and reduce PPI use in selected patients, but overall evidence quality is low to very low, with limitations including small sample sizes, short follow-up, risk of bias, and inconsistent objective reflux control.

See cited systematic reviews and RCTs

Patient selection signals: Patients studied commonly had chronic GERD despite PPI therapy or were PPI-dependent and sought alternatives; some device studies required objective pathologic acid exposure and limited hiatal hernia size in trial inclusion criteria.

Specific thresholds vary by study

Safety considerations: Some devices had serious adverse events in early experience (e.g., MUSE reported severe perforations), and long-term durability is uncertain; centers should report outcomes and monitor for complications.

Early procedural iterations had higher complication rates

Typical trial inclusion

Studies generally enrolled patients meeting ALL of the following:

Typical study inclusion criteria: Adult patients with chronic or refractory GERD on daily PPI therapy (≥ 6 months), abnormal objective testing in some trials (e.g., abnormal pH or DeMeester score), hiatal hernia ≤ specified size in certain trials (e.g., ≤ 2 cm or < 3 cm), and absence of advanced esophagitis or Barrett's esophagus in many device trials.As reported in individual trials

Specific thresholds vary by study; see trial-level documentation

Benefits and risks

Observed benefits and risks reported in the literature:

Reported benefits: TIF and related endoscopic fundoplication procedures: symptom score reductions and decreased PPI use in many patients; MSA (LINX): high rates of PPI discontinuation, improved GERD-HRQL, and patient satisfaction in multiple series and meta-analyses.Varies by study

Long-term durability and comparative effectiveness vs Nissen remain uncertain

Reported risks and limitations: Reported risks include postoperative dysphagia after MSA, need for dilation, device explantation/removal, potential for erosion, heterogeneity in outcomes for TIF, and insufficient objective reflux control in some endoscopic therapies.Numeric rates reported in studies (see sources)

Adverse event rates and follow-up durations vary across studies

MSA (LINX) — candidate criteria

Covered when ALL of the following are met

MSA candidate criteria: Patient has moderate to severe regurgitation despite optimized PPI therapy; objective evidence of GERD (e.g., abnormal pH testing); anatomy suitable for device (hiatal hernia <3 cm in key trials); absence of severe esophagitis or Barrett's esophagus as excluded in trials.Hiatal hernia < 3 cm; BMI and other trial-specific criteria applied per study

Based on trial inclusion/exclusion criteria and guideline recommendations

Guideline support

Guideline-based considerations

Guideline support: Professional societies (ACG) recommend antireflux surgery for patients with objective GERD and consider MSA as an alternative to fundoplication for regurgitation refractory to medical management.

Strong recommendation (ACG) for considering MSA for regurgitation

Coverage additions (GES and surgical pyloroplasty)

Key coverage determinations described in the revision history

GES for refractory gastroparesis: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Language relocated into this policy from a prior UnitedHealthcare policy

Surgical pyloroplasty

Surgical pyloroplasty for refractory gastroparesis: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Added to Coverage Rationale and Policy History

This policy addresses a range of minimally invasive endoscopic and laparoscopic therapies and devices intended to treat upper gastrointestinal conditions including gastroparesis, achalasia, diffuse esophageal spasm, and gastroesophageal reflux disease (GERD). Descriptions of procedural approaches include radiofrequency energy (Stretta), endoscopic plication/suturing (e.g., GERDx™, EsophyX/TIF, MUSE), injectable or implantable bulking agents (e.g., Plexiglas®, Durasphere®), and implantable mechanical devices (e.g., LINX magnetic sphincter).

Therapies differ in mechanism and evidence base — for example, Radiofrequency (Stretta) delivers thermal lesions around the lower esophageal sphincter, while endoscopic fundoplication/TIF or MUSE create a transoral plication or stapled partial fundoplication, and polymer injections aim to bulk the proximal LES. The policy groups procedures by indication and available evidence to guide coverage and documentation requirements.

Several procedures included in this policy lack adequate comparative evidence, long-term follow-up, or objective outcome documentation. The policy notes that endoscopic therapies, injection/implantation techniques, and some device-based approaches have generally been evaluated in small, heterogeneous studies with methodological limitations (for example, lack of randomization or control groups), which limits confidence in comparative effectiveness versus established surgical options.

When considering coverage for such procedures, reviewers should expect clear clinical justification and supporting documentation because the evidence base does not consistently demonstrate durable benefit or objective physiologic improvement compared with standard treatments.

The policy summarizes that G-POEM (gastric peroral endoscopic myotomy), Z-POEM (Zenker's POEM), and Stretta (endoscopic radiofrequency ablation) have insufficient high-quality evidence to be considered proven. Available studies are often small, single-center, or retrospective and show variable results with limited long-term data.

Specifically, G-POEM evidence is described as inadequate to support safety and efficacy for gastroparesis outside of research settings; Stretta trials and meta-analyses provide low to very low quality evidence with mixed results versus sham or surgical approaches; and Z-POEM data are limited and at high risk of bias, leaving comparative durability and safety uncertain.

Multiple endoscopic therapies for GERD demonstrate symptomatic improvements that may not be durable over the long term. Case series and long-term follow-up reports document progressive loss of symptomatic benefit for some procedures (e.g., endoluminal plication, polymer injection) with rising rates of symptom recurrence by 60 months and limited objective improvement in pH or manometry measures.

Network and systematic reviews of transoral fundoplication (TIF/EsophyX) and other endoscopic antireflux procedures note short-term patient satisfaction and symptom reduction but identify limited physiologic improvement and insufficient long-term comparative data to support these procedures as durable alternatives to laparoscopic fundoplication or continued medical therapy.

Injectable polymer bulking agents and implantation techniques (examples: Plexiglas® polymethylmethacrylate, Durasphere® pyrolytic carbon-coated beads) are summarized as having insufficient evidence to establish long-term safety and effectiveness for GERD. Small case series show short-term reductions in PPI use or symptom scores in some cohorts, but these studies are limited by small sample sizes, lack of controls, and inconsistent objective outcome data.

Given these limitations, polymer injection and implantation techniques remain investigational for GERD and are not considered proven therapies in this policy absent more robust randomized, controlled, and longer-term outcome data.

Use of devices outside their FDA-cleared or -approved indications is identified as off-label and may affect coverage decisions. For example, Durasphere is FDA-approved for urologic use and its application for esophageal reflux would be considered off-label; use of such devices for non‑approved gastrointestinal indications may prompt additional review or non‑coverage.

The policy also lists device approvals and premarket notifications (e.g., LINX PMA P100049, GERDx 510(k) K233240) in the FDA section; when devices are used within labeled indications, FDA status is informational but does not alone dictate coverage.

Language that previously characterized functional lumen imaging probe technology as unproven and not medically necessary for diagnosing achalasia was removed in the current revision. The deletion reflects an update of the policy's exclusions and diagnostic technology statements rather than a new explicit coverage restriction.

Determinations of benefit coverage must align with applicable federal, state, and contractual plan terms. Where the policy content conflicts with specific federal, state, or contractual requirements, those requirements govern the decision. Providers should verify plan-level rules in conjunction with this policy when requesting authorization.

Scope statements clarify intended indications: POEM is established as proven and medically necessary for achalasia and diffuse esophageal spasm. In contrast, POEM for other indications (e.g., Zenker's diverticulum) and G-POEM for gastroparesis are described as unproven and not medically necessary due to insufficient evidence. Z-POEM is similarly noted as investigational with limited long-term data.

These scope distinctions reflect current evidence-based positions and guide prior authorization and documentation expectations for each specific endoscopic therapy.

Open-label and single-center GES series have reported symptomatic improvements, but the policy highlights limitations of these data. Meta-analyses and systematic reviews (e.g., Levinthal & Bielefeldt) show that randomized crossover studies did not find consistent differences in total symptom severity, while multiple open-label series report improvements — a pattern that may reflect baseline severity differences and regression to the mean.

Because open-label cohorts (for example, a 151‑patient single-center Enterra cohort) lack control groups and have variable follow-up, their findings should be interpreted cautiously and require documentation of refractory disease and prior therapies when considered for coverage.

Endoscopic therapies for GERD, including radiofrequency Stretta and various endoscopic plication or suturing techniques, are described in the policy as unproven or of low to very low quality evidence. Randomized and observational studies are heterogeneous, and some sham‑controlled trials have failed to show clear benefit, leaving Stretta and several endoscopic treatments without consistent high-quality support.

As a result, these endoscopic GERD therapies are generally considered investigational or not proven to be medically necessary for routine use absent stronger comparative evidence and appropriate patient selection documentation.

Some endoscopic therapies produce transient symptomatic improvements that diminish over time. For example, long-term follow-up of endoluminal plication or polymer injection procedures shows symptomatic benefit up to 12 months but progressive loss of effect with increasing rates of nonresponse by 60 months and little objective improvement in pH or manometry testing.

This pattern underscores the need to document both short-term outcomes and longer-term durability when evaluating these therapies for coverage.

Systematic reviews and network meta-analyses of TIF (EsophyX) indicate that while TIF can provide short-term symptom and quality-of-life improvements, some analyses do not recommend TIF as a long-term alternative to proton pump inhibitor (PPI) therapy or laparoscopic Nissen fundoplication due to limited physiologic improvement and inconsistent long-term comparative data.

Consequently, TIF may be considered selectively for patients meeting trial-like criteria but is not uniformly endorsed as a durable replacement for established surgical or medical management.

Procedures that lack evidence of long-term benefit, or those performed without documented diagnostic criteria and prior appropriate medical therapy, may be excluded from coverage or considered investigational. The policy advises that requests for such procedures should include clear documentation of indications, prior conservative treatments, and objective testing where applicable to support medical necessity.

Examples cited include endoscopic antireflux procedures performed without documented PPI trial or objective reflux confirmation, and novel procedures with only uncontrolled case series evidence.

The current policy revision does not add new explicit 'Not Medically Necessary' statements in this excerpt; instead, it updates coverage rationale (for example, adding GES and surgical pyloroplasty statements) and expands documentation requirements used during reviews.

Existing statements classifying many endoscopic GERD therapies, G-POEM, and POEM for non‑achalasia indications as unproven or not medically necessary remain in place based on the evidence summarized elsewhere in the policy.

Procedure and Device Coding

Upper endoscopy / esophageal proceduresCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral [i.e., peroral endoscopic myotomy (POEM)].
43499	Unlisted procedure, esophagus.

Gastric neurostimulator / GES proceduresCPT

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
43999	Unlisted procedure, stomach.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

Procedures and devices discussed (narrative)mixed

Enterra	GES system (Medtronic) referenced in studies
POEM	Per-oral endoscopic myotomy procedure referenced across multiple studies
LHM	Laparoscopic Heller myotomy (compared with POEM)

No procedure or diagnosis codes listed in this document sectionmixed

No codes listed

Procedure / Device descriptions (no codes listed)mixed

No explicit CPT/HCPCS/ICD-10 codes provided in this section of the document.

Device PMA identifiersmixed

P100049

FDA PMA number for LINX Reflux Management System

Recent 510(k) device clearancesmixed

K233240

FDA 510(k) number for GERDx-System (Product Code ODE)

Applicable CPT Codes AddedCPT

43647
43648
43659
43881
43882
64590
64595

Applicable CPT codes addedCPT

43647	CPT code added (description per policy applicable codes list)
43648	CPT code added (description per policy applicable codes list)
43659	CPT code added (description per policy applicable codes list)
43881	CPT code added (description per policy applicable codes list)
43882	CPT code added (description per policy applicable codes list)
64590	CPT code added (description per policy applicable codes list)
64595	CPT code added (description per policy applicable codes list)

Eckardt score for success

DefinitionEckardt score — validated symptom score used to assess achalasia severity; clinical success in trials commonly defined as score ≤ 3.

ComponentsIncludes symptoms of dysphagia, regurgitation, chest pain, and weight loss as captured in the Eckardt instrument.

Use in trialsWerner et al. (2019) used Eckardt ≤ 3 to define 2‑year clinical success for POEM vs LHM (83.0% vs 81.7%).

GCSI severe gastroparesis threshold used in RCT

Threshold

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Prior authorization and code list

Prior authorization is required for many of the procedures and devices discussed in this policy. The applicable CPT/HCPCS codes are provided for reference and are used in authorization and claims review; listing does not guarantee coverage. Providers should request authorization before scheduling services and include complete supporting documentation.

Prior authorization required for novel endoscopic and implantable devices/procedures (see code list above).
Code list provided for reference only; inclusion does not imply coverage or payment.

Prior Authorization

Prior authorization: demonstrate refractory disease

Authorization requests for GES, pyloroplasty, or other interventions for gastroparesis should document that the disease is refractory to recommended stepwise medical therapies and conservative measures. Refractory disease means persistent, clinically significant symptoms despite appropriate trials of first-line and second-line therapies.

Document trials of dietary modification and prokinetic agents.
Document trials of antiemetic therapy and adequacy of symptom control.

Clinical Background and Evidence Context

Gastroparesis is a disorder of delayed gastric emptying that commonly presents with nausea, vomiting, early satiety, and weight loss; it can lead to nutritional complications. Diagnosis requires objective evidence of delayed gastric emptying in symptomatic patients, with gastric scintigraphy typically regarded as the reference standard for measuring gastric emptying.

Treatment options are stepwise, beginning with dietary modification and prokinetic/antiemetic medications; this policy identifies gastric electrical stimulation (GES) and surgical pyloroplasty as proven options for refractory gastroparesis that has failed other therapies, while endoscopic pyloric interventions and G-POEM remain investigational in many contexts.

Definitions

Achalasia definition

DefinitionAchalasia — primary esophageal motor disorder characterized by degeneration of the myenteric plexus causing impaired relaxation of the esophagogastric junction and loss of organized peristalsis.

Clinical featuresPresents with dysphagia, regurgitation, and may be classified by manometric subtypes (I–III) which guide management choices.

Relevance to interventionsPOEM is considered a proven, medically necessary treatment option for achalasia per the policy when selection criteria are met.

Diffuse Esophageal Spasm definition

DefinitionDiffuse esophageal spasm — rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions accompanied by dysphagia.

Clinical presentation

Policy Update Summary

2026-04-01material_changeLatest

Added coverage language establishing gastric electrical stimulation (GES) as proven and medically necessary for refractory gastroparesis and added surgical pyloroplasty (open or laparoscopic) as proven and medically necessary for refractory gastroparesis; relocated GES language from a different policy into this policy.

2026-04-01documentation_update

Expanded Medical Records Documentation Used for Reviews to require that medical records fully support medical necessity, include relevant history, exam, and diagnostic tests, be legible, maintained in the record, and made available upon request.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Pennsylvania Only)

Policy CodePolicy CS079PA.T

Change TypeMaterial additions and coding updates

Effective DateApr 1, 2026

Next Review Date

Key ActionSubmit prior authorization with documentation of refractory symptoms, prior conservative treatments, and supporting diagnostic testing to demonstrate medical necessity.

SourceLink

On This Page

Trials included patients refractory to PPIs

A 2020 sham-controlled RCT showed no significant benefit; evidence remains low quality

GCSI > 2.3 — threshold used to define severe gastroparesis in the Martinek 2022 RCT of G-POEM vs sham.

ContextParticipants had severe or refractory gastroparesis > 6 months; primary outcome was ≥50% reduction in total GCSI.

Trial size and findingsMartinek RCT randomized 41 patients; 15/21 treatment vs 4/20 sham achieved success at 6 months; noted 10 SAEs with 3 related to G-POEM.

Body mass index (BMI) — inclusion criterion for MUSE

Inclusion BMI limitBMI < 40 kg/m2 — inclusion criterion used in the MUSE (Medigus Ultrasonic Surgical Endostapler) study (Testoni et al.).

Age range contextMUSE study included individuals >18 and <70 years and required availability for long-term follow-up.

Outcomes reportedApproximately 75% had ≥50% GERD‑HRQL/RSI improvement at 6 months; two severe perforation events reported in early experience.

BMI threshold used in RCT inclusion

BMI thresholdBMI < 35 kg/m2 — inclusion criterion used in the randomized trial comparing MSA (LINX) to PPI therapy (Bell et al.).

Other trial entry requirementsTrial also required abnormal pH testing and hiatal hernia < 3 cm; absence of Barrett's esophagus or high-grade esophagitis was required.

RelevanceBMI cutoff used to define anatomical/operative candidacy in key MSA RCTs and cohort studies evaluating efficacy and safety.

Hiatal hernia size limit in RCT inclusion

Hiatal hernia size limitHiatal hernia < 3 cm — size limit used in key randomized trials evaluating MSA (LINX) inclusion criteria.

Assessment modalityHiatal hernia size ascertained by endoscopy in trial entry criteria for the Bell et al. randomized study.

ImplicationAnatomical suitability (hiatal hernia ≤3 cm) is a common device-trial selection signal for MSA candidacy and may inform preoperative evaluation.

Document prior interventions (e.g., pyloroplasty) if applicable and outcomes.

Documentation Required

Documentation supports medical necessity

Medical records must fully support the medical necessity of the requested procedure. Incomplete documentation may delay authorization or result in denial. Records should be legible and made available upon request.

Include relevant medical history and physical examination.
Include results of pertinent diagnostic tests (e.g., gastric emptying study, pH testing, endoscopy, manometry).
Provide symptom scores and documented response to prior therapies.

Denial Risk

Evidence limitations for single-center GES series

Some key clinical evidence cited in this policy derives from single-center series (for example, Heckert et al. on Enterra GES). These studies may have limited follow-up, no control groups, and selection biases; authorization reviewers may request additional supporting documentation or long-term outcome data.

Single-center GES series may not be generalizable; provide multicenter or comparative data when available.
If only single-center evidence is provided, include detailed patient selection criteria and follow-up outcomes.

Denial Risk

Evidence limitations for Z-POEM

Z-POEM (Zenker's POEM) is a novel technique with limited high-quality comparative data and short-term follow-up in published studies. The literature is dominated by retrospective and single-center reports; reviewers may require additional evidence or consider the procedure investigational in certain settings.

Provide prospective or comparative data when available; document operator expertise and center volume.
Long-term recurrence and reintervention rates are incompletely characterized — include available follow-up beyond 1 year if possible.

Denial Risk

Evidence insufficiency may trigger denial

When evidence is limited or absent (novel techniques, small RCTs, short follow-up), requests may be denied or held for further review. Justification should include objective measures, prior therapy failures, and rationale for choosing the requested procedure over established alternatives.

Document why standard, less-invasive, or better-studied treatments were unsuitable or failed.
Include objective outcome measures (symptom scores, physiologic testing) and expected clinical benefit.

Denial Risk

Off-label device use — risk of non-coverage

Some devices (e.g., Enterra for GES has an HDE; LINX has PMA-approved indications) have specific FDA labeling and labeling-based limitations. Off-label use of devices or use outside FDA–cleared/approved indications may not be covered and is subject to additional review or denial.

If requesting device use outside labeled indications, provide rationale, supporting peer-reviewed evidence, and prior therapy documentation.
Note: FDA approval alone does not guarantee coverage; HDE/PMA status affects review but is informational only.

Documentation Required

Recommended preoperative diagnostic documentation

Authorization for magnetic sphincter augmentation (LINX) or other antireflux procedures generally requires preoperative objective confirmation of GERD and prior medication trials. Long-term MSA cohorts report specific preoperative testing that should be provided with the request.

Required preoperative diagnostics: validated symptom questionnaire (e.g., GERD-HRQL), upper endoscopy (to exclude Barrett's > Grade B/C esophagitis), ambulatory pH monitoring (abnormal DeMeester or equivalent), esophageal manometry, and imaging (barium swallow) when indicated.
Document prior PPI therapy (dose and duration) and response; include PPI trial of at least 8 weeks where applicable.

Step Therapy

Stepwise treatment expectations

Stepwise treatment is expected before consideration of procedural or device therapy. Conservative measures and guideline-recommended medical therapy should be attempted and documented unless contraindicated or not tolerated.

Initial therapy: lifestyle and dietary modification and optimization of PPI therapy for GERD.
For gastroparesis: dietary modification, prokinetic agents, antiemetics, and nutrition support as indicated.
Document trials of therapies and objective outcomes before escalation to procedural options.

Step Therapy

Stepwise treatment before experimental procedures

Experimental or novel procedures (e.g., endoscopic plication, some endoluminal antireflux procedures, G-POEM in select indications) should be considered only after standard, evidence-supported treatments have failed and when the patient understands the experimental nature and limited long-term data.

Require documentation of failed standard therapies and explanation why conventional surgical options are unsuitable.
Recommend enrollment in clinical trial or registry when available and documentation of informed consent regarding investigational status.

Step Therapy

PPI therapy as first-line

For GERD, proton pump inhibitor (PPI) therapy is the recommended first-line medical treatment. Authorization for procedural antireflux interventions typically requires an adequate trial of PPI therapy with documentation of response or failure.

Document PPI type, dose, duration, and degree of symptom control.
If PPI-intolerant or contraindicated, document reason and alternative medical management tried.

Step Therapy

Medical therapy prior to MSA

Medical therapy should be attempted prior to magnetic sphincter augmentation (MSA). Randomized trials comparing MSA to twice-daily PPI therapy required participants to have failed or had inadequate control on PPI therapy, and prior medical management should be documented in authorization requests.

Document at least an 8-week trial of optimized PPI therapy (or documented intolerance) and objective evidence of reflux (pH testing) where indicated.
Include GERD-HRQL or RDQ scores and prior response to medical therapy.

Patients typically present with dysphagia and chest pain; diagnosis is based on manometry patterns of uncoordinated contractions.

Implication for POEMPOEM is an indicated approach for diffuse esophageal spasm when clinical criteria are met, as reflected in policy coverage for spastic disorders.

GERD definition

DefinitionGastroesophageal reflux disease (GERD) — condition in which the lower esophageal sphincter relaxes too often or weakens, allowing reflux of stomach contents into the esophagus.

ComplicationsPersistent GERD may lead to severe esophagitis, strictures, Barrett's metaplasia, or esophageal adenocarcinoma.

Diagnostic contextObjective testing (e.g., abnormal pH monitoring) and prior PPI response are commonly required in trials evaluating procedural therapies for GERD.

Gastroparesis definition (policy updated)

DefinitionGastroparesis — disorder of delayed or absent gastric motility (delayed gastric emptying); diagnosis requires objective evidence of delayed gastric emptying in symptomatic patients.

SymptomsFrequent nausea and vomiting, early satiety, bloating, postprandial fullness, and epigastric pain; can lead to metabolic and nutritional complications.

Diagnostic standardScintigraphic gastric emptying testing is the reference standard for measuring delayed gastric emptying.

Humanitarian Use Device (HUD)

DefinitionHumanitarian Use Device (HUD) — FDA designation referenced by ACG indicating a device may be considered for medically refractory diabetic or idiopathic gastroparesis when other therapies have failed (example: Enterra GES has an HDE).

Policy contextACG notes GES may be considered as a HUD for medically refractory gastroparesis; Enterra has FDA HDE approval for chronic intractable nausea and vomiting due to diabetic or idiopathic gastroparesis.

ImplicationHUD designation supports conditional consideration of device therapy in select refractory patients but does not alone determine coverage and requires documentation of refractory disease.

Eckardt score

DefinitionEckardt score — validated symptom score used to assess achalasia severity and define treatment success; trials commonly define success as Eckardt ≤ 3.

Use in outcome assessmentEckardt score was the primary validated questionnaire in the Werner RCT to measure clinical success at 2 years.

Success thresholdEckardt ≤ 3 used as the success definition in randomized trials of POEM versus surgical myotomy.

Z-POEM definition

DefinitionZ-POEM — Zenker's peroral endoscopic myotomy; an endoscopic myotomy technique for treating Zenker's diverticulum with limited and short-term evidence regarding long-term comparative effectiveness.

Evidence limitationsAvailable studies are largely retrospective with high risk of bias and limited follow-up beyond one year; long-term durability and recurrence data are uncertain.

Clinical implicationZ-POEM may be considered in expert centers but is investigational/limited given insufficient high-quality comparative data.

G-POEM definition

DefinitionG-POEM — gastric peroral endoscopic myotomy; endoscopic pyloric myotomy proposed to treat refractory gastroparesis but with insufficient high-quality evidence to establish long-term safety and efficacy.

Trial signalsSmall RCT (Martinek 2022) used GCSI >2.3 to enroll severe gastroparesis patients and showed benefit at 6 months but had limited sample size and adverse events.

Policy stancePolicy considers G-POEM unproven and not medically necessary for treatment of gastroparesis based on current evidence limitations.

Stretta definition

DefinitionStretta — endoscopic radiofrequency energy therapy that delivers RF to the gastroesophageal junction intended to treat GERD.

Evidence summaryEvidence is low to very low quality with mixed results; a 2020 double‑blind sham‑controlled RCT (Zerbib) showed no significant benefit versus sham at 24 and 48 weeks.

Long-term case seriesSome small series report symptom improvement up to 10 years, but these are uncontrolled and of limited generalizability.

Stretta (duplicate definitional entry)

Definition (duplicate)Stretta — endoscopic radiofrequency procedure intended to treat GERD by delivering radiofrequency energy to the gastroesophageal junction; controlled trials and reviews show inconsistent efficacy.

Key RCTZerbib et al. (2020) randomized 62 patients and found no significant difference between Stretta and sham for primary symptom outcomes at 24 and 48 weeks.

Clinical implicationGiven inconsistent RCT evidence and low-quality observational data, Stretta is considered unproven for routine use without stronger evidence.

EFTP / TIF / EsophyX definition

DefinitionEndoscopic full‑thickness fundoplication (EFTP) / TIF / EsophyX — transoral techniques to create a fundoplication or plication at the gastroesophageal junction without external incisions.

EvidenceRandomized and controlled trials report symptom improvement and reduced PPI use in selected patients, but long‑term durability and comparative effectiveness versus fundoplication remain uncertain.

Outcome signalsEFTP demonstrated ~65.7% achieving ≥50% GERD‑HRQL improvement vs 2.9% sham at 12 months in a randomized trial (Kalapala et al.).

MUSE definition

DefinitionMUSE (Medigus Ultrasonic Surgical Endostapler) — transoral stapling device for incisionless fundoplication evaluated in case series and prospective cohorts.

Inclusion criteria exampleMUSE studies enrolled adults 18–70 years with chronic GERD and BMI < 40 kg/m2; required follow-up availability.

Outcomes and risksReported ~73% off‑PPI improvement at 6 months in early series; two severe perforations occurred in early experience necessitating device/procedure modifications.

TIF (EsophyX) definition

DefinitionTIF (EsophyX) — transoral incisionless fundoplication using the EsophyX system to create a fundoplication without external incisions.

EvidenceSystematic reviews and RCTs report symptom improvement, reduced PPI use, and remission in selected chronic PPI‑dependent GERD patients, but long‑term comparative evidence is limited.

Trial exampleHåkansson et al. (TIF2) double‑blind sham RCT showed longer remission time and higher remission rates at 6 months vs sham in chronic PPI users (n=44).

MSA / LINX definition

DefinitionMagnetic sphincter augmentation (MSA) / LINX — implantable ring of magnetic beads placed laparoscopically around the LES to augment sphincter function and reduce reflux.

Evidence summarySystematic reviews and RCTs report high rates of PPI discontinuation and symptom control; MSA trials typically required BMI <35 kg/m2, abnormal pH testing, and hiatal hernia <3 cm.

Safety signalsPostoperative dysphagia and need for endoscopic dilation are relatively common; device explantation and rare erosion reported in long‑term cohorts.

Polymer injection/implantation definition

DefinitionPolymer injection/implantation (e.g., Durasphere, Plexiglas) — injectable bulking agents or implants intended to augment the gastroesophageal junction; evidence is insufficient to establish long‑term safety and efficacy.

Evidence limitationsAvailable studies are small case series or heterogeneous trials; systematic reviews conclude evidence is inadequate for routine use.

Regulatory noteDurasphere is FDA‑approved for certain indications as a bulking agent, but off‑label use for GERD would require evaluation and is controversial in policy context.

Magnetic sphincter augmentation (MSA) — duplicate

Definition (duplicate)Magnetic sphincter augmentation (MSA) — laparoscopic implantation of a magnetic ring (LINX) around the GEJ to augment sphincter function and reduce reflux; evaluated for symptom control and PPI discontinuation.

Trial criteriaKey trials required BMI <35 kg/m2, abnormal pH testing, hiatal hernia <3 cm, and absence of advanced esophagitis/Barrett's.

OutcomesRandomized trials report high regurgitation control and PPI cessation but note dysphagia as a frequent postoperative issue.

Enterra Therapy System definition

DefinitionEnterra Therapy System — an FDA Humanitarian Device Exemption gastric electrical stimulation device indicated for drug‑refractory nausea and vomiting secondary to diabetic or idiopathic gastroparesis in adults 18–70 years.

Label exclusionsEnterra labeling advises against use in patients with gastric obstruction/pseudo‑obstruction, prior gastric resection or fundoplication, eating disorders, primary swallowing disorders, seizures, chemical dependency, or psychogenic vomiting.

Policy relevanceEnterra's HDE status supports conditional use of GES in refractory gastroparesis per ACG guidance, but coverage requires meeting clinical documentation requirements.

Gastroparesis definition updated (policy)

Definition (updated)Gastroparesis — updated policy definition: a disorder of delayed or absent gastric motility (delayed gastric emptying); diagnosis requires objective evidence of delayed gastric emptying in symptomatic patients (scintigraphy is the reference standard).

Clinical consequencesMay cause frequent nausea/vomiting, nutritional complications, hospitalization for metabolic derangements, and impaired glycemic control in diabetic patients.

Documentation requirementPolicy history emphasizes that medical records must fully support medical necessity (relevant history, exam, diagnostic test results) when assessing coverage for gastroparesis therapies.

Gastroparesis definition updated (duplicate)

Definition (duplicate updated)Gastroparesis — policy definitions updated to reinforce diagnostic requirement of objective delayed gastric emptying in symptomatic patients; documentation must be available upon request.

Reference standardScintigraphic gastric emptying testing cited as the reference standard for diagnosis and assessment of gastroparesis severity.

Policy change noteRevision history entries explicitly note the 'Gastroparesis' definition was updated in the Definitions section of the policy.

2026-04-01coding_update

Added applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to the policy's Applicable Codes list.

2026-04-01definition_update

Updated the Definitions section to revise the definition of 'Gastroparesis'.

2026-04-01supporting_information_update

Updated supporting sections (Description of Services, Clinical Evidence, FDA, and References) and archived the previous policy version CS079PA.S.